rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

David L. Grange

Director

Company insider

Files Form 4 as: Director, Tonix Pharmaceuticals Holding; Chief Executive Officer, Pharmaceutical Product Development.

Every Form 4 they filed

In numbers

Trades disclosed
52
Buys
0
Sells
7
Bought
$0
Sold
$3.4M
Companies
2
Companies where not an officer
1
First trade
3 Jan 2006
Last trade
12 May 2026
Last filed
14 May 2026

Companies traded

Where they are an officer
Pharmaceutical Product DevelopmentDirector, Officer · last 28 Feb 20110 buys · 7 sells
Everywhere else they filed: board seats, 10% stakes, other companies
TNXP Tonix Pharmaceuticals HoldingDirector · Biotechnology · last 12 May 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
12 May 2026filed 14 May 2026TNXP Tonix Pharmaceuticals Holdingoption or derivative · BiotechnologySEC FORM 4 Code A—22,700 at $0.00filing
12 May 2026filed 14 May 2026TNXP Tonix Pharmaceuticals Holdingoption or derivative · BiotechnologySEC FORM 4 Code A—22,700 at $0.00filing
13 May 2025filed 15 May 2025TNXP Tonix Pharmaceuticals Holdingoption or derivative · BiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
23 May 2024filed 24 May 2024TNXP Tonix Pharmaceuticals Holdingoption or derivative · BiotechnologySEC FORM 4 Code A—104,621 at $0.00filing
8 May 2023filed 10 May 2023TNXP Tonix Pharmaceuticals Holdingoption or derivative · BiotechnologySEC FORM 4 Code A—60,000 at $0.00filing
9 May 2022filed 11 May 2022TNXP Tonix Pharmaceuticals Holdingoption or derivative · BiotechnologySEC FORM 4 Code A—2,131,500 at $0.00filing
10 May 2021filed 12 May 2021TNXP Tonix Pharmaceuticals Holdingoption or derivative · BiotechnologySEC FORM 4 Code A—270,882 at $0.00filing
4 May 2020filed 6 May 2020TNXP Tonix Pharmaceuticals Holdingoption or derivative · BiotechnologySEC FORM 4 Code A—75,000 at $0.00filing
6 May 2019filed 8 May 2019TNXP Tonix Pharmaceuticals Holdingoption or derivative · BiotechnologySEC FORM 4 Code A—30,000 at $0.00filing
12 Jun 2018filed 13 Jun 2018TNXP Tonix Pharmaceuticals Holdingoption or derivative · BiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
13 Feb 2018filed 15 Feb 2018TNXP Tonix Pharmaceuticals Holdingoption or derivative · BiotechnologySEC FORM 4 Code A—7,000 at $0.00filing
28 Feb 2011filed 1 Mar 2011Pharmaceutical Product Developmentoption or derivativeSEC FORM 4 Code M—34,501 at $0.00filing
28 Feb 2011filed 1 Mar 2011Pharmaceutical Product DevelopmentSEC FORM 4 Code M$706K34,501 at $20.45filing
28 Feb 2011filed 1 Mar 2011Pharmaceutical Product DevelopmentSEC FORM 4 Sold$897K34,501 at $26.00filing
3 Nov 2010filed 4 Nov 2010Pharmaceutical Product Developmentoption or derivativeSEC FORM 4 Code M—51,380 at $0.00filing
3 Nov 2010filed 4 Nov 2010Pharmaceutical Product DevelopmentSEC FORM 4 Code M$1.1M51,380 at $21.98filing
3 Nov 2010filed 4 Nov 2010Pharmaceutical Product DevelopmentSEC FORM 4 Sold$1.3M51,380 at $25.71filing
2 Nov 2010filed 4 Nov 2010Pharmaceutical Product Developmentoption or derivativeSEC FORM 4 Code M—373 at $0.00filing
2 Nov 2010filed 4 Nov 2010Pharmaceutical Product DevelopmentSEC FORM 4 Code M$8,199373 at $21.98filing
2 Nov 2010filed 4 Nov 2010Pharmaceutical Product DevelopmentSEC FORM 4 Sold$9,698373 at $26.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed7

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.